Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.

Fanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, Fran├ža LR, Reilly PA, Kermer P, Wowern FV, Lane DA, Butcher K.

Thromb Haemost. 2019 Aug 30. doi: 10.1055/s-0039-1695771. [Epub ahead of print]

2.

Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.

White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R.

Blood Press Monit. 2008 Feb;13(1):21-7. doi: 10.1097/MBP.0b013e3282f3859d. Erratum in: Blood Press Monit. 2008 Aug;13(4):241.

PMID:
18199920
3.

Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.

White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM.

J Clin Hypertens (Greenwich). 2006 Sep;8(9):626-33.

4.

Tumor necrosis factor during experimental lipopolysaccharide-induced otitis media.

DeMaria TF, Murwin DM.

Laryngoscope. 1997 Mar;107(3):369-72.

PMID:
9121315
7.

Supplemental Content

Loading ...
Support Center